ClinicalTrials.gg
CompletedNCT06644417Updated Jan 26, 2026

Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

A Phase 2 interventional study of TQA3605 tablets plus NAs and TQA3605 Placebo plus NAs in HBV Infection With LLV, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 19 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a phase II multicenter, randomized, double-blind, placebo controlled study designed to evaluate the efficacy and safety in LLV subjects and demonstrate that TQA3605 tablets combined with oral NAs drugs can improve the efficacy and safety of LLV subjects compared with oral NAs drug.

02

Conditions studied

  • HBV Infection With LLV
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-65 (including boundary values), male or female.
  • At the time of screening, etiological or clinical or pathological evidence of virus infection has been more than 1 year; HBsAg positive, 10 IU/mL \<HBV DNA≤2000 IU/mL, ≤3× (upper limit of normal); No obvious cirrhosis was found by the researchers.
  • Continuous administration of any nucleoside (acid) analogues for more than 1 year and a stable regimen of ≥6 months prior to screening.
  • Able to communicate well with researchers, understand and comply with the requirements of the study, understand and sign the .
  • Male subjects with fertile female partners or female subjects of childbearing age were willing to voluntarily take effective measures within 3 months after screening.

Exclusion criteria

Exclusion Criteria:

  • Pregnant (positive pregnancy test) or breastfeeding women.
  • Co-infection with other viruses such as hepatitis A virus, virus, hepatitis D virus, hepatitis E virus, , syphilis.
  • A history of cirrhosis or evidence of significant fibrosis or cirrhosis at pre-screening/screening time.
  • The subject had a history of hepatocellular carcinoma (HCC) before or at the time of screening, or was suspected of HCC.
  • A history of malignant tumors within 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection.
  • Subjects with other chronic liver diseases, including but not limited to liver disease, alcoholic liver disease, and hepatolenticular degeneration.
  • Have previously received organ transplantation and bone marrow transplantation.
  • Abnormal laboratory examination indicators that do not meet the requirements of the program during screening.
  • Poorly controlled thyroid disease, or thyroid dysfunction.
  • Autoimmune diseases include but are not limited to: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, psoriasis, autoimmune uveitis, etc.;
  • In addition to liver disease, there are significant systemic or major diseases, including recent congestive heart failure, unstable coronary heart disease, arterial revasodilation, respiratory disease, digestive disease, renal insufficiency, stroke, , organ transplantation, psychiatric disease, etc. Uncontrolled systemic disease: poor blood pressure control; Diabetes has poor blood sugar control.
  • Received any systemic antitumor (including radiation) or therapy (including biological immune inhibitors), or immunomodulatory therapy (including non-biological immunomodulatory oral drugs) in the 6 months prior to screening.
  • Receiving high doses of systemic within 3 months prior to the screening period.
  • A history of alcohol and drug abuse within 1 year prior to the screening period.
  • Blood transfusion ≤2 months before screening and/or blood donation ≤1 month before screening. Note: Participants were not allowed to donate blood throughout the study period.
  • Have a history of allergy to the experimental drug or its .
  • Participated in clinical trials of core protein allosteric regulators.
  • The subject has participated in a clinical trial and received the drug during the period prior to the first administration of the study: 5 half-lives or twice the duration of the biological effect of the study treatment or 90 days (if the half-life or duration is unknown).
  • History or status of cardiovascular disease: history of risk factors for tip torsion ventricular tachycardia, including unexplained syncope, known long syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory tests. Family history of long QT syndrome or Brugada syndrome. The (ECG) showed clinically significant abnormalities. Heart Rate (HR)≤45 bpm.
  • Those that researchers believe should not be included.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Placebo comparator
    TQA3605 Placebo plus NAs

    TQA3605 placebo plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks

    Drug: TQA3605 Placebo plus NAs

  • Experimental
    100mg TQA3605 tablets plus NAs

    100mg TQA3605 tablets plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks

    Drug: TQA3605 tablets plus NAs

  • Experimental
    200mg TQA3605 tablets plus NAs

    200mg TQA3605 tablets plus NAs drug was administered for 24 weeks and NAs was continued until 32 weeks

    Drug: TQA3605 tablets plus NAs

Interventions

  • DrugTQA3605 tablets plus NAs

    TQA3605 tablets is core protein regulator

  • DrugTQA3605 Placebo plus NAs

    Placebo without drug substance

06

What researchers measure

Primary outcomes

  1. HBV DNA (Hepatitis B virus Deoxyribonucleic Acid)

    Percentage of subjects with HBV DNA below the lower limit of quantitative detection (\<10 IU/mL) at 24 weeks of treatment

    Time frame: 24 weeks

Secondary outcomes

  1. Incidence and severity of Adverse events (AEs)

    The incidence and severity of AEs were determined by changes in physical examination, vital signs, electrocardiogram, and laboratory tests

    Time frame: 32 weeks

  2. Incidence and severity of serious adverse events (SAEs)

    The incidence and severity of SAEs were determined by changes in physical examination, vital signs, electrocardiogram, and laboratory tests

    Time frame: 32 weeks

  3. HBV DNA (<10 IU/mL)

    Percentage of subjects with HBV DNA below the lower limit of quantitative detection (\<10 IU/mL)

    Time frame: Weeks 12, Weeks 16, Weeks 28, Weeks 32

  4. HBV DNA (<10 IU/mL)

    Percentage of subjects with HBV DNA below the lower limit of quantitative detection (\<10 IU/mL)

    Time frame: Weeks 12, Weeks 16, Weeks 24, Weeks 28, Weeks 32

  5. Hepatitis B e antigen (HBeAg) Serology

    Percentage of subjects with HBeAg serologic clearance and/or serologic conversion (for HBeAg positive at baseline only)

    Time frame: Weeks 12, Weeks 24, Weeks 32

  6. Alanine Aminotransferase (ALT) relapse rate

    Renormalize ALT over time in subjects with baseline ALT\>upper limit of normal (ULN) in the absence of enzyme-lowering Liver protection medicine

    Time frame: Weeks 12, Weeks 24, Weeks 32

  7. Breakthroughs in virology

    Percentage of subjects with a virological breakthrough

    Time frame: Weeks 12, Weeks 24, Weeks 32

  8. Actual values and changes of HbsAg (Hepatitis B Surface Antigen)

    Actual values and changes of HbsAg over time relative to baseline

    Time frame: Weeks 12, Weeks 24, Weeks 32

  9. Actual values and changes of HBeAg

    Actual values and changes of HBeAg over time relative to baseline

    Time frame: Weeks 12, Weeks 24, Weeks 32

  10. Actual values and changes of HBV DNA

    Actual values and changes of HBV DNA over time relative to baseline

    Time frame: Weeks 12, Weeks 24, Weeks 32

  11. HBV RNA (Hepatitis B virus Ribonucleic Acid)

    Actual values and changes of HBV RNA over time relative to baseline

    Time frame: Weeks 12, Weeks 24, Weeks 32

  12. Actual values and changes of Human Hepatitis B virus core antigen - associated antigen (HbcrAg)

    Actual values and changes of HbcrAg over time relative to baseline

    Time frame: Weeks 12, Weeks 24, Weeks 32

  13. (Cmax, ss) Steady-state maximum concentration

    Steady-state maximum concentration of TQA3605

    Time frame: Day 1, Day 29, Day 57, Day 85, Day 113, Day 169

  14. (Cmin, ss) Steady state minimum concentration

    Steady-state minimum concentration of TQA3605

    Time frame: Day 1, Day 29, Day 57, Day 85, Day 113, Day 169

07

Study locations

19 sites
  • Beijing Ditan Hospital Capital Medical University
    Beijing, Beijing Municipality 100015, China
  • Beijing Youan Hospital, Capital Medical Universitybeijing Institute of Hepatology
    Beijing, Beijing Municipality 100054, China
  • Meng Chao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian 350001, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou 550002, China
  • Zunyi Medical University Affiliated Hospital
    Zunyi, Guizhou 563000, China
  • Zhengzhou No.6 peoples Hospital
    Zhengzhou, Henan 450000, China
  • The Second XIANGYA Hospital Of Central South University
    Changsha, Hunan 410008, China
  • Yueyang Central Hospital
    Yueyang, Hunan 414000, China
  • Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu 210000, China
  • The Fifth People's Hospital of Suzhou
    Suzhou, Jiangsu 215131, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
  • The sixth people's Hospital Of Shenyang
    Shenyang, Liaoning 110001, China
  • Shandong Public Health Clinical Center
    Jinan, Shandong 250102, China
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200000, China
  • Shanghai Tongren Hospital
    Shanghai, Shanghai Municipality 200336, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi’an, Shanxi 710000, China
  • The First Affiliated Hospital Zhejiang University School Of Medicine
    Hangzhou, Zhejiang 310006, China
  • Lishui People's Hospital
    Lishui, Zhejiang 323000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Aug 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 16, 2024
StartActual
Nov 14, 2024
Primary completionActual
Aug 25, 2025
CompletionActual
Dec 10, 2025
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06644417
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Nov 14, 2024
Primary completion
Aug 25, 2025
Completion
Dec 10, 2025
Last update
Jan 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion